

CONTENTS

NOTE TO THE READER	1
LIST OF PARTICIPANTS	3
PREAMBLE.....	7
1. Background.....	9
2. Objective and Scope	9
3. Selection of Topics for Monographs	10
4. Data for Monographs	11
5. The Working Group	11
6. Working Procedures	11
7. Exposure Data.....	12
8. Studies of Cancer in Humans	14
9. Studies of Cancer in Experimental Animals.....	17
10. Other Data Relevant to an Evaluation of Carcinogenicity and its Mechanisms	20
11. Summary of Data Reported	22
12. Evaluation	23
13. References.....	28
GENERAL REMARKS	33
MONOGRAPH ON HUMAN PAPILLOMAVIRUSES	45
Human Papillomaviruses	47
1. Human Papillomavirus (HPV) Infection.....	47
1.1 Evolution, structure and molecular biology	47
1.1.1 Introduction	47
1.1.2 Structure of the viruses	48
1.1.3 Classification of papillomaviruses	52
1.1.4 Evolution of papillomaviruses.....	63
1.1.5 Function of viral proteins	66
1.1.6 Regulation of gene expression.....	75
1.1.7 Methylation status of cytosine in CpG sequences in the viral genome	77
1.1.8 Replication.....	78
1.2 Serological response	79
1.2.1 Antigenic properties of HPV virion proteins	80
1.2.2 Immune response to papillomavirus infection	83

1.3	Methods for the detection of HPV infection	87
1.3.1	Non-molecular techniques for the detection of genital HPV infection	87
1.3.2	Detection of HPV proteins in infected tissues	91
1.3.3	Detection of HPV nucleic acids	92
1.3.4	Detection of HPV infections and HPV-associated cancers by serological assays	106
1.4	Natural history and epidemiology of HPV infection	112
1.4.1	Introduction	112
1.4.2	Transmission and acquisition.....	113
1.4.3	Prevalence of HPV infection	117
1.4.4	Incidence, persistence and clearance.....	124
1.4.5	Microscopic abnormalities	128
1.4.6	Progression to precancer	129
1.4.7	Progression of lesions	130
1.4.8	Accuracy and reliability of measurements	132
1.4.9	Serology.....	132
1.4.10	Other sites	132
1.5	Pathology of HPV infection of the genital tract and evidence therefrom for progression to malignancy	136
1.5.1	Evolution of concepts and terminology.....	136
1.5.2	Temporal and spatial relationships between precursors of cervical cancer and invasive cancer	140
1.5.3	Histological changes in HPV-related lesions of the lower female genital tract	142
1.5.4	Pathology of cutaneous HPV infection and non-melanoma skin cancer	148
1.6	Non-malignant clinical lesions (other than precursors of cancer) of established HPV etiology	150
1.6.1	Anogenital area	151
1.6.2	Upper respiratory tract.....	153
1.6.3	Oral cavity	154
1.6.4	Conjunctiva	155
1.6.5	Skin	155
1.7	Therapy and vaccination.....	156
1.7.1	Therapy of benign disease.....	156
1.7.2	Therapy of precancerous lesions	165
1.7.3	Therapy of invasive cancer	167
1.7.4	Therapeutic vaccination.....	173
1.8	Prophylaxis	177
2.	Studies of Cancer in Humans	179
2.1	Methodological concerns	179
2.2	Cancer of the cervix	183
2.2.1	Historical perspective	183

2.2.2	Data on pooled HPV types	184
2.2.3	Data on type-specific HPV	192
2.3	Cancer at other anogenital sites	209
2.3.1	Cancer of the vulva	209
2.3.2	Cancer of the vagina	213
2.3.3	Cancer of the penis	215
2.3.4	Cancer of the anus	215
2.4	Cancer of the upper aerodigestive tract	222
2.4.1	Cancer of the oral cavity	222
2.4.2	Cancer of the oropharynx and tonsil	230
2.4.3	Cancer of the oesophagus	235
2.4.4	Cancer of the larynx	239
2.5	Cancer of the skin and conjunctiva.....	245
2.5.1	Cancer of the skin	245
2.5.2	Cancer of the eye and conjunctiva	259
2.6	Cancer at other sites	260
2.6.1	Cancer of the nose and nasal sinuses	260
2.6.2	Cancer of the lung	261
2.6.3	Cancer of the colon and the rectum.....	267
2.6.4	Cancer of the breast.....	268
2.6.5	Cancer of the ovary	269
2.6.6	Cancer of the prostate	269
2.6.7	Cancer of the urinary bladder and urethra.....	270
2.7	Co-factors of HPV in cervical cancer.....	278
2.7.1	Non-infectious co-factors for cervical cancer	278
2.7.2	Infectious co-factors	313
2.8	Special populations	327
2.8.1	Skin cancer in patients with epidermodysplasia verruciformis (EV) and HPV infection	327
2.8.2	Studies of the incidence of HPV-associated neoplasia in transplant patients	332
2.8.3	Studies in human immunodeficiency virus (HIV)-infected persons	355
3.	Studies of Animal Papillomaviruses	412
3.1	Non-human primate papillomaviruses	412
3.2	Bovine papillomavirus (BPV)	414
3.2.1	Heterogeneity of BPV	414
3.2.2	BPV 1.....	416
3.2.3	BPV 2.....	417
3.2.4	BPV 3.....	420
3.2.5	BPV 4.....	420
3.2.6	BPV 5 and BPV 6	422
3.2.7	Unknown BPV types that cause cancer in cattle.....	422
3.2.8	BPV in equine sarcoids	423

3.3	Equine papillomavirus (EqPV).....	425
3.4	Papillomavirus in cervidae	425
3.5	Cottontail rabbit papillomavirus (CRPV).....	425
3.5.1	Species specificity	426
3.5.2	Viral multiplication and tumour induction	426
3.5.3	Co-factors for tumour induction and progression	426
3.5.4	Latency of CRPV	427
3.5.5	CRPV in transgenic rabbits	427
3.6	Domestic rabbit oral papillomavirus (ROPV)	428
3.7	Ovine papillomatosis (OPV).....	428
3.8	<i>Mastomys natalensis</i> papillomavirus (MnPV)	430
3.9	Mouse papillomavirus (MmPV).....	431
3.10	Canine oral papillomavirus (COPV).....	431
3.11	Feline papillomas	431
3.12	Avian papillomavirus	432
4.	Molecular Mechanisms of HPV-induced Carcinogenesis.....	432
4.1	Experimental data that support the carcinogenicity of specific HPV genotypes and analyse the mechanism of HPV-linked carcinogenesis	432
4.1.1	Transforming capacity of HPV	432
4.1.2	Biochemical properties of HPV proteins.....	435
4.1.3	Biological properties of HPV proteins	437
4.1.4	Experimental evidence for a role of mucosal high-risk HPV in malignant conversion and in human cervical cancer	440
4.1.5	Interactions between HPV and environmental agents.....	446
4.1.6	Transgenic models for HPV-associated cancers	457
4.2	Immune mechanisms and HPV-associated neoplasia.....	460
4.2.1	Immunosuppression.....	460
4.2.2	Histological studies	460
4.2.3	Cell-mediated immunity	461
4.2.4	Major histocompatibility complex (MHC)	463
4.2.5	Modulation of innate immune responses by HPV	464
5.	Summary of Data Reported and Evaluation	465
5.1	Human papillomavirus (HPV) infection.....	465
5.2	Human carcinogenicity data	468
5.3	Animal carcinogenicity data	473
5.4	Other relevant data	474
5.5	Evaluation	476
6.	References	477
	LIST OF ABBREVIATIONS.....	633
	CUMULATIVE INDEX TO THE <i>MONOGRAPHS</i> SERIES	637

NOTE TO THE READER

The term ‘carcinogenic risk’ in the *IARC Monographs* series is taken to mean that an agent is capable of causing cancer under some circumstances. The *Monographs* evaluate cancer hazards, despite the historical presence of the word ‘risks’ in the title.

Inclusion of an agent in the *Monographs* does not imply that it is a carcinogen, only that the published data have been examined. Equally, the fact that an agent has not yet been evaluated in a monograph does not mean that it is not carcinogenic.

The evaluations of carcinogenic risk are made by international working groups of independent scientists and are qualitative in nature. No recommendation is given for regulation or legislation.

Anyone who is aware of published data that may alter the evaluation of the carcinogenic risk of an agent to humans is encouraged to make this information available to the Carcinogen Identification and Evaluation Group, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France, in order that the agent may be considered for re-evaluation by a future Working Group.

Although every effort is made to prepare the monographs as accurately as possible, mistakes may occur. Readers are requested to communicate any errors to the Carcinogen Identification and Evaluation Group, so that corrections can be reported in future volumes.